Cortecs, a young UK-based company with Australian origins, has a growing portfolio of patent applications offering worldwide protection for potential products. Fields of particular interest include diagnosis of Helicobacter pylori and other infections, vaccine technology, solubilisation and drug delivery, and enzymes in intracellular signal transduction. From information concerning pending patent applications, it seems that therapeutic targeting is to be an important feature of Cortecs’ future development work.